Sagent Pharmaceuticals, Inc. a manufacturer of specialty pharmaceutical products with an emphasis on the injectables market, has appointed its current executive vice president and chief legal officer, Michael Logerfo, as president, effective April 15, 2015.
In his new role as president, Mr. Logerfo will lead the company's Executive Management Committee, will continue to have primary responsibility over the company's strategic business development and legal functions, and will report to the chairman of the board.
Mr. Logerfo has served as executive vice president, chief legal officer and corporate secretary of Sagent since March 2012. Prior to that, Mr. Logerfo had served as corporate vice president since March 2007, chief legal officer since April 2010, and secretary since September 2010. From March 2007 to August 2008, Mr. Logerfo served as chief operating officer of the former KSCP joint venture, now Sagent (China) Pharmaceuticals (SCP). From October 1999 to January 2006, Mr. Logerfo held the positions of president and chief executive officer of Flavine Holding Co. and its affiliates, a privately held group engaged in the development and sale of active pharmaceutical ingredients.
Mr. Logerfo also has been a lawyer in private practice. Mr. Logerfo is admitted to practice law in New York and New Jersey, and he received a BA in government and a JD from Georgetown University.
Source: Sagent Pharmaceuticals